Loading
Combining pembrolizumab with the kinase inhibitor axitinib lengthened survival and delayed progression compared with sunitinib as first treatment for advanced clear cell kidney cancer, across all risk groups.
Phase 3 trial of 861 patients with previously untreated advanced clear cell renal cell carcinoma randomised to pembrolizumab plus axitinib or sunitinib.
At 12.8 months, overall survival at one year was 89.9 versus 78.3 percent (hazard ratio 0.53), median progression-free survival 15.1 versus 11.1 months and response 59.3 versus 35.7 percent; the final analysis confirmed a survival benefit (median 47.2 versus 40.8 months).
Immunotherapy plus a VEGF kinase inhibitor is a first-line standard for advanced clear cell kidney cancer in all risk groups; comparable regimens include nivolumab-cabozantinib and lenvatinib-pembrolizumab.
Shares Clear cell renal cell carcinoma, Sunitinib, New England Journal of Medicine.
Shares Sunitinib, New England Journal of Medicine.
Shares Axitinib, Pembrolizumab.
Shares KEYNOTE-426, Pembrolizumab.
Shares Clear cell renal cell carcinoma, Sunitinib.
Shares Axitinib, Pembrolizumab.
Shares KEYNOTE-426, Pembrolizumab.
Shares Sunitinib, Pembrolizumab.